Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices 63827 

Under section 402 of the American 

Recovery and Reinvestment Act 

(Recovery Act), 42 U.S.C. 16421a, Public 

Law 111–5, 123 Stat. 141, Div A, Title 

IV, section 402 (2009) (adding Section 

301 to the Hoover Power Plant Act of 

1984 [Public Law 98–381, Title III, 

section 301]), Western may borrow 

funds from the United States Treasury 

to construct, finance, facilitate, plan, 

operate, maintain, and/or study 

construction of new or upgraded electric 

power transmission lines and related 

facilities with at least one terminus in 

Western’s marketing area, that deliver or 

facilitate the delivery of power from 

renewable resources constructed or 

reasonably expected to be constructed 

after the date of enactment of the 

Recovery Act. In order to implement 

section 402, on March 4, 2009, Western 

published a Notice of Proposed Program 

and Request for Public Comments in the 

Federal Register (74 FR 9391) 

describing its proposed Transmission 

Infrastructure Program (TIP) and 

soliciting public input on that program. 

After considering the comments 

received on its March 4 notice, Western 

published its final TIP Notice of 

Program on May 14, 2009 (74 FR 22732). 

Western also published a Notice of 

Availability of Request for Interest on 

March 4, 2009, (74 FR 9391) that 

solicited interest in proposed 

transmission projects that resulted in 

the submission of over 200 SOIs, 

including a SOI for the TWE Project. 

Western is evaluating its potential 

participation in the TWE Project. The 

TWE Project is proposed as a 725-mile, 

3,000-megawatt (MW), 600-kilovolt 

(kV), two-terminal, direct-current (DC) 

transmission system with terminals in 

Wyoming and Nevada and a potential 

interconnection at the Intermountain 

Power Project near Delta, Utah. The 

northern substation/converter station 

would be located near the Platte 

substation, in Carbon County, Wyoming. 

The southern substation/converter 

station would be located in southern 

Nevada near the Eldorado Valley. The 

northern terminal of the line is 

anticipated to interconnect with the 

planned 500-kV alternating current (AC) 

system that PacifiCorp has proposed as 

part of the Energy Gateway project. The 

southern terminal of the line would be 

interconnected with the 500-kV AC 

substations within the Eldorado Valley, 

where power can be wheeled to the 

various markets in the region. The 

estimated cost for the project is $3 

billion and the planned in-service date 

is 2015. Western anticipates that it will 

be able to make approximately 250 MW 

of unidirectional surplus transmission 

capacity available from the Carbon 

County, Wyoming area to the Clark 

County, Nevada area. 

In this notice, Western solicits SOIs to 

allow Western to determine the level of 

interest in Western’s portion of longterm firm transmission service on the 

TWE Project. Information received 

through this effort may assist Western in 

acquiring TWE Project support and 

approval. Specifically, Western is 

soliciting any and all interest from 

entities looking to transfer energy from 

the Carbon County, Wyoming area to the 

Clark County, Nevada area. Western’s 

rate would be cost-based; however, 

Western does not currently have 

sufficient information to estimate a rate. 

An expression of interest in purchasing 

this long-term firm transmission service 

made by submitting a SOI is not binding 

or promissory. SOIs submitted with 

respect to this notice should, at a 

minimum, include the following 

information: 

1. Name and general description of 

the entity submitting the SOI. 

2. Name, mailing address, telephone 

number, facsimile number, and e-mail 

address of that entity’s primary contact. 

3. Preferred interconnection points. 

4. Description of the resources the 

proposed TWE Project transmission 

path would facilitate delivery of, 

including type(s) of resources, general 

location of generation and load or 

markets, existing interconnection 

requests, anticipated resource capacity 

and capacity factor of resource, 

estimated commercial operation date of 

generation, and any other information 

that would be useful in evaluating 

submitted SOIs. 

5. The amount of transmission 

capacity and desired term of agreement 

for long-term firm transmission service 

and the interconnection or receipt 

points on the proposed path. 

6. A general description of financing 

for generation. 

7. A statement of financial stability. 

Entities intending to submit a SOI 

should request from Western a SOI 

Evaluation Agreement. Entities must 

then execute the SOI Evaluation 

Agreement and pay a non-refundable 

SOI Evaluation Cost in the sum of 

$5,000. Western intends to use these 

funds to defray its cost in evaluating the 

SOIs and to continue its efforts in 

considering its potential participation in 

the TWE Project. By submitting an SOI 

and associated Evaluation Cost, 

submitters will be included for future 

consideration for Western’s capacity in 

the TWE Project should the project 

proceed and Western participate in it. 

Western will treat data submitted by 

entities in this process, including 

financing arrangements with other 

parties, in accordance with the Freedom 

of Information Act (FOIA). Participants 

may identify for confidential treatment 

all or part of a submitted document 

under the FOIA exemption for 

‘‘Confidential Business Information’’ 

with appropriate markings. Such 

markings will be considered in the 

event a FOIA request for the information 

is received. 

Environmental Compliance 

In compliance with the National 

Environmental Policy Act of 1969 

(NEPA) (42 U.S.C. 4321, et seq.), the 

Council on Environmental Quality 

Regulations for implementing NEPA (40 

CFR Parts 1500–1508) and the DOE 

NEPA Implementing Procedures and 

Guidelines (10 CFR Part 1021), Western 

has determined that this action is 

categorically excluded from further 

NEPA analysis. Future actions under 

this authority will undergo appropriate 

NEPA analysis. 

Dated: October 7, 2010. 

Timothy J. Meeks, 

Administrator. 

[FR Doc. 2010–26143 Filed 10–15–10; 8:45 am] 

BILLING CODE 6450–01–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[FRL–9214–5; Docket ID No. EPA–HQ–ORD– 

2010–0744] 

Integrated Risk Information System 

(IRIS); Request for Chemical 

Substance Nominations for 2011 

Program 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Request for chemical substance 

nominations for the IRIS 2011 Program. 

SUMMARY: EPA’s IRIS is a human health 

assessment program that evaluates 

quantitative and qualitative risk 

information on effects that may result 

from exposure to specific chemical 

substances found in the environment. 

EPA is soliciting public nominations for 

chemical substances for its 2011 agenda. 

EPA invites the public to submit 

nominations for substances to be 

considered for an assessment or 

reassessment in its IRIS Program in 

accordance with the instructions 

provided at the end of this notice. 

DATES: Nominations must be submitted 

within 60 days of the publication of this 

notice. The 60-day period begins 

October 18, 2010, and ends December 

17, 2010. 

mstockstill on DSKH9S0YB1PROD with NOTICES

63828 Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices 

ADDRESSES: Nominations may be 

submitted electronically via http:// 

www.regulations.gov, by e-mail, by mail, 

by facsimile, or by hand delivery/ 

courier. Please follow the detailed 

instructions provided in the 

SUPPLEMENTARY INFORMATION section of 

this notice. 

FOR FURTHER INFORMATION CONTACT: For 

information on the IRIS Program, 

contact Abdel Kadry, PhD, Program 

Director, National Center for 

Environmental Assessment (mail code 

8601PY), Office of Research and 

Development, U.S. Environmental 

Protection Agency, Washington, DC 

20460; or send electronic mail inquiries 

to: FRNquestions@epa.gov. For general 

questions about access to IRIS or the 

content of IRIS, please call the IRIS 

Hotline at (202) 566–1676 or send 

electronic mail inquiries to 

hotline.iris@epa.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

EPA’s IRIS is a human health 

assessment program that evaluates 

quantitative and qualitative risk 

information on effects that may result 

from exposure to specific chemical 

substances found in the environment. 

Through the IRIS Program, EPA 

provides the highest quality sciencebased human health assessments to 

support the Agency’s regulatory 

activities. The IRIS database contains 

information for more than 540 chemical 

substances that can be used to support 

the first two steps (hazard identification 

and dose-response evaluation) of the 

risk assessment process. When 

supported by available data, IRIS 

provides oral reference doses (RfDs) and 

inhalation reference concentrations 

(RfCs) for chronic noncancer health 

effects, as well as assessments of 

potential carcinogenic effects resulting 

from chronic exposure. Combined with 

specific exposure information, 

government and private entities use IRIS 

to help characterize public health risks 

of chemical substances in site-specific 

situations and thereby support risk 

management decisions designed to 

protect public health. 

From FY2008 to the present, the 

following IRIS assessments were 

completed and posted on the IRIS 

database: 

acrylamide ....................................................................................................................................................................... 79–06–1 

bromobenzene ................................................................................................................................................................ 108–86–1 

carbon tetrachloride ........................................................................................................................................................ 56–23–5 

cerium oxide and cerium compounds ............................................................................................................................ 1306–38–3 

chlordecone (kepone) ..................................................................................................................................................... 143–50–0 

chloroprene ..................................................................................................................................................................... 126–99–8 

decabromodiphenyl ether ............................................................................................................................................... 1163–19–5 

cis-1,2-dichloroethylene .................................................................................................................................................. 156–59–2 

trans-1,2-dichloroethylene .............................................................................................................................................. 156–60–5 

1,4-dioxane (oral) ............................................................................................................................................................ 123–91–1 

ethylene glycol monobutyl ether (EGBE) ....................................................................................................................... 111–76–2 

hexabromodiphenyl ether ............................................................................................................................................... 68631–49–2 

2-hexanone ..................................................................................................................................................................... 591–78–6 

hydrogen cyanide ........................................................................................................................................................... 74–90–8 

nitrobenzene ................................................................................................................................................................... 98–95–3 

pentabromodiphenyl ether .............................................................................................................................................. 60348–60–9 

pentachlorophenol .......................................................................................................................................................... 87–86–5 

propionaldehyde ............................................................................................................................................................. 123–38–6 

tetrabromodiphenyl ether ................................................................................................................................................ 5436–43–1 

1,1,2,2-tetrachloroethane ................................................................................................................................................ 79–34–5 

thallium ............................................................................................................................................................................ 7440–28–0 

1,2,3-trichloropropane ..................................................................................................................................................... 96–18–4 

The assessments listed below are 

currently on the IRIS agenda. The status 

and planned milestone dates can be 

found on the IRIS track system, 

accessible on the IRIS Web site (http:// 

www.epa.gov/iris). All cancer and 

noncancer health endpoints due to 

chronic exposure are being assessed 

unless otherwise noted. Not all of the 

assessments on the IRIS agenda have 

been started, but most are in the various 

review steps of the IRIS process. The 

remainder will start draft development 

as resources become available. 

acetaldehyde ................................................................................................................................................................... 75–07–0 

acrylonitrile ...................................................................................................................................................................... 107–13–1 

alkylates .......................................................................................................................................................................... various 

ammonia ......................................................................................................................................................................... 7664–41–7 

tert-amyl methyl ether (TAME) ....................................................................................................................................... 994–05–8 

antimony ......................................................................................................................................................................... 7440–36–0 

arsenic, inorganic (cancer) ............................................................................................................................................. 7440–38–2 

arsenic, inorganic (noncancer) ....................................................................................................................................... 7440–38–2 

benzo(a)pyrene ............................................................................................................................................................... 50–32–8 

beryllium (cancer) ........................................................................................................................................................... 7440–41–7 

biphenyl ........................................................................................................................................................................... 92–52–4 

bisphenol A ..................................................................................................................................................................... 80–05–7 

n-butanol ......................................................................................................................................................................... 71–36–3 

tert-butanol ...................................................................................................................................................................... 75–65–0 

butyl benzyl phthalate ..................................................................................................................................................... 85–68–7 

cadmium ......................................................................................................................................................................... 7440–43–9 

carbonyl sulfide ............................................................................................................................................................... 463–58–1 

chloroethane ................................................................................................................................................................... 75–00–3 

chloroform ....................................................................................................................................................................... 67–66–3 

chromium VI .................................................................................................................................................................... 18540–29–9 

cobalt .............................................................................................................................................................................. 7440–48–4 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices 63829 

copper ............................................................................................................................................................................. 7440–50–8 

di-n-butyl phthalate ......................................................................................................................................................... 84–74–2 

1,2-dichlorobenzene ....................................................................................................................................................... 95–50–1 

1,3-dichlorobenzene ....................................................................................................................................................... 541–73–1 

1,4-dichlorobenzene ....................................................................................................................................................... 106–46–7 

1,2-dichloroethane (ethylene dichloride) ........................................................................................................................ 107–06–2 

dichloromethane (methylene chloride) ........................................................................................................................... 75–09–2 

diethyl phthalate .............................................................................................................................................................. 84–66–2 

di(2-ethylhexyl)adipate .................................................................................................................................................... 103–23–1 

di(2-ethylhexyl) phthalate ................................................................................................................................................ 117–81–7 

diisobutyl phthalate ......................................................................................................................................................... 84–69–5 

diisononyl phthalate ........................................................................................................................................................ 58033–90–2 

diisopropyl ether (DIPE) ................................................................................................................................................. 108–20–3 

4,4’-dimethyl-3-oxahexane (TAEE) ................................................................................................................................. 919–94–8 

1,4-dioxane (inhalation) .................................................................................................................................................. 123–91–1 

dipentyl phthalate ............................................................................................................................................................ 131–18–0 

ethanol ............................................................................................................................................................................ 64–17–5 

ethyl tertiary butyl ether (ETBE) ..................................................................................................................................... 637–92–3 

ethylbenzene ................................................................................................................................................................... 100–41–4 

ethylene oxide (cancer) .................................................................................................................................................. 75–21–8 

formaldehyde .................................................................................................................................................................. 50–00–0 

hexabromocyclododecane (mixed stereoisomers) ......................................................................................................... 3194–55–6, 25637–99–5 

hexachlorobutadiene ....................................................................................................................................................... 87–68–3 

hexachloroethane ........................................................................................................................................................... 67–72–1 

hexahydro-1,3,5-trinitro-triazine (RDX) ........................................................................................................................... 121–82–4 

isopropanol ..................................................................................................................................................................... 67–63–0 

Libby amphibole asbestos .............................................................................................................................................. 1332–21–4 

manganese ..................................................................................................................................................................... 7439–9 

methanol ......................................................................................................................................................................... l67–56–1 

methyl tert-butyl ether (MTBE) ....................................................................................................................................... 1634–04–4 

mirex ............................................................................................................................................................................... 2385–85–5 

naphthalene .................................................................................................................................................................... 91–20–3 

nickel (soluble salts) ....................................................................................................................................................... various 

halogenated platinum salts and platinum compounds ................................................................................................... various 

polychlorinated biphenyls (PCBs) (noncancer) .............................................................................................................. various 

polycyclic aromatic hydrocarbon (PAH) mixtures ........................................................................................................... various 

refractory ceramic fibers ................................................................................................................................................. not applicable 

styrene ............................................................................................................................................................................ 100–42–5 

2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds ......................................................................................... 1746–01–6, various 

tetrachloroethylene (perchloroethylene) ......................................................................................................................... 127–18–4 

tetrahydrofuran ................................................................................................................................................................ 109–99–9 

trichloroacetic acid .......................................................................................................................................................... 76–03–9 

trichloroethylene .............................................................................................................................................................. 79–01–6 

1,2,4-trimethylbenzene ................................................................................................................................................... 95–63–6 

1,3,5-trimethylbenzene ................................................................................................................................................... 108–67–8 

tungsten and related compounds ................................................................................................................................... 7440–33–7, various 

urea ................................................................................................................................................................................. 57–13–6 

uranium (natural) ............................................................................................................................................................ 7440–61–1 

vanadium pentoxide ........................................................................................................................................................ 1314–62–1 

vinyl acetate .................................................................................................................................................................... 108–05–4 

The alkylates, listed above, are a 

distillation fraction of petroleum and 

are present in gasoline. Common 

alkylates found in gasoline for which 

IRIS assessments have not been recently 

completed include n-heptane, 

methylcyclohexane, 2-methylbutane, 2- 

methylpentane, 3-methylpentane, noctane, 2,3,3-trimethylpentane, 2,3,4- 

trimethylpentane, and 2,2,5- 

trimethylhexane. EPA will evaluate the 

feasibility of conducting an assessment 

of alkylates, the approach to be taken in 

the assessment, and the identities of the 

compounds that will be assessed. 

The following phthalates have been 

added to the IRIS agenda: Diisobutyl 

phthalate, diisononyl phthalate, and 

dipentyl phthalate. These additions to 

the IRIS agenda are in response to 

recommendations made by the National 

Academy of Sciences in the report, 

‘‘Phthalates and Cumulative Risk 

Assessment—The Tasks Ahead’’ (NAS, 

2008). 

Perfluorooctanoic acid—ammonium 

salt (PFOA) and perfluorooctane 

sulfonate—potassium salt (PFOS) have 

been withdrawn from the IRIS agenda. 

In December 2009, EPA published the 

‘‘Long-Chain Perfluorinated Chemicals 

(PFCs) Action Plan Summary’’ (http://

www.epa.gov/opptintr/

existingchemicals/pubs/actionplans/

pfcs.html), part of EPA Administrator 

Lisa Jackson’s comprehensive approach 

to enhance the Agency’s current 

chemicals management program under 

the Toxic Substances Control Act. PFOA 

and PFOS are included in the Agency’s 

action plan for this class of chemicals. 

The listing of asbestos in the IRIS 

agenda has been revised to specify 

Libby amphibole asbestos. EPA is 

focusing on the Libby amphibole in 

order to respond to needs of the Agency 

and the Libby community. The 

assessment for weathered toxaphene has 

been withdrawn because of lack of data 

to support an IRIS assessment. 

Today’s notice invites voluntary 

public nominations for chemical 

substances not already listed in this 

notice. Today’s notice also invites 

comments on assessments on the 

current IRIS agenda. To nominate a 

substance, please complete the form 

below and submit it to EPA by one of 

the methods detailed below. A fill-andprint version of this form can be found 

on the IRIS Web site, http://www.epa.

gov/iris, under IRIS Agenda. 

Nominations and comments are most 

mstockstill on DSKH9S0YB1PROD with NOTICES

63830 Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices 

useful if they identify the nominator 

(including full name, title, affiliation, 

mailing address, e-mail address, and 

telephone number) and provide 

information on the criteria EPA uses to 

evaluate the priority of the chemicals: 

Identification of nominator: 

Nominator’s name: 

Title: 

Affiliation: 

Telephone No.: 

Address: 

e-mail address: 

Chemical Substance Name: 

Common Synonym(s), if any: 

CAS No.: 

Information for Prioritizing 

Nominations 

1. What is the potential public health 

impact for this chemical? 

2. Is this assessment needed to fulfill 

a chemical-specific EPA mandate or 

program need (e.g., statutory, regulatory, 

or court-ordered deadline)? Please 

describe the mandate or program need. 

When is the assessment needed? 

3. Is this assessment a priority for 

stakeholders outside of EPA (e.g., states, 

tribes, local governments, 

environmental organizations, industries, 

or other IRIS users)? Why is it a 

priority? 

4. Are you aware of other assessments 

of this substance that may be available 

to EPA (e.g., an EPA program has 

assessed this substance, but it has not 

received Agency-wide IRIS review, a 

state or other federal agency has an 

assessment, or another government or 

private organization has assessed this 

substance)? If possible, please provide 

specific information to allow EPA to 

locate and obtain the assessment. 

5. For substances being nominated for 

IRIS reassessment, what, if any, 

significant new scientific data or risk 

assessment methodology is available 

that you believe would be likely to 

appreciably change the existing IRIS 

assessment? Please provide specific 

citations and other information that 

would allow EPA to locate and obtain 

the papers or data. 

6. Are you aware of other factors that 

would make this substance a priority for 

IRIS assessment (e.g., widespread 

exposure, expected toxicity, or 

potentially susceptible populations)? 

II. How To Submit Nominations and 

Comments to the Docket at http://www.

regulations.gov 

—http://www.regulations.gov: Follow 

the on-line instructions for submitting 

comments. 

—E-Mail: ORD.Docket@epa.gov. 

—Hand Delivery: The OEI Docket is 

located in the EPA Headquarters 

Docket Center, EPA West Building, 

Room 3334, 1301 Constitution Ave., 

NW., Washington, DC. The EPA 

Docket Center Public Reading Room is 

open from 8:30 a.m. to 4:30 p.m., 

Eastern Standard Time, Monday 

through Friday, excluding federal 

holidays. The telephone number for 

the Public Reading Room is (202) 

566–1744. Deliveries are only 

accepted during the docket’s normal 

hours of operation, and special 

arrangements should be made for 

deliveries of boxed information. 

Consult EPA’s Web site at http://www.

epa.gov/epahome/dockets.htm for 

current information on docket 

operations, locations and telephone 

numbers. 

Instructions: Direct your nominations 

to Docket ID No. EPA–HQ–ORD–2010– 

0744. Please ensure that your comments 

are submitted within the specified 

nomination period. Nominations 

received after the closing date will be 

marked ‘‘late,’’ and may be considered 

only if time permits. It is EPA’s policy 

to include all comments it receives in 

the public docket without change and to 

make the comments available online at 

http://www.regulations.gov, including 

any personal information provided, 

unless comments include information 

claimed to be Confidential Business 

Information (CBI) or other information 

whose disclosure is restricted by statute. 

Do not submit information that you 

consider to be CBI or otherwise 

protected through http://www.

regulations.gov or e-mail. The http://

www.regulations.gov Web site is an 

‘‘anonymous access’’ system, which 

means EPA will not know your identity 

or contact information unless you 

provide it in the body of your 

comments. If you send e-mail comments 

directly to EPA without going through 

http://www.regulations.gov, your e-mail 

address will be automatically captured 

and included as part of the comments 

that are placed in the public docket and 

made available on the Internet. If you 

submit electronic comments, EPA 

recommends that you include your 

name and other contact information in 

the body of your comments and with 

any disk or CD–ROM you submit. If EPA 

cannot read your comments due to 

technical difficulties and cannot contact 

you for clarification, EPA may not be 

able to consider your comments. 

Electronic files should avoid the use of 

special characters, any form of 

encryption, and be free of any defects or 

viruses. For additional information 

about EPA’s public docket, visit the EPA 

Docket Center homepage at http://www.

epa.gov/epahome/dockets.htm. 

Docket: Documents in the docket are 

listed in the http://www.regulations.gov 

index. Although listed in the index, 

some information is not publicly 

available, e.g., CBI or other information 

whose disclosure is restricted by statute. 

Certain other materials, such as 

copyrighted material, are publicly 

available only in hard copy. Publicly 

available docket materials are available 

either electronically in http://www.

regulations.gov or in hard copy at the 

OEI Docket in the EPA Headquarters 

Docket Center. 

Dated: October 12, 2010. 

Darrell Winner, 

Acting Director, National Center for 

Environmental Assessment. 

[FR Doc. 2010–26159 Filed 10–15–10; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL COMMUNICATIONS 

COMMISSION 

[DA 10–1937] 

Consumer Advisory Committee 

AGENCY: Federal Communications 

Commission. 

ACTION: Notice. 

SUMMARY: The Commission announces 

the next meeting date and agenda of its 

Consumer Advisory Committee 

(‘‘Committee’’). The purpose of the 

Committee is to make recommendations 

to the Commission regarding consumer 

issues within the jurisdiction of the 

Commission and to facilitate the 

participation of all consumers in 

proceedings before the Commission. 

DATES: The meeting of the Committee 

will take place on Wednesday, 

November 10, 2010, 9 a.m. to 4 p.m., at 

the Commission’s Headquarters 

Building, Room TW–C305. 

ADDRESSES: Federal Communications 

Commission, 445 12th Street, SW., 

Washington, DC 20554. 

FOR FURTHER INFORMATION CONTACT: 

Scott Marshall, Consumer and 

Governmental Affairs Bureau, (202) 

418–2809 (voice), (202) 418–0179 

(TTY), or e-mail Scott.Marshall@fcc.gov. 

SUPPLEMENTARY INFORMATION: This is a 

summary of the Commission’s 

document DA 10–1937 released October 

7, 2010, announcing the agenda, date 

and time of the Committee’s next 

meeting. At its November 10, 2010 

meeting, the Committee is expected to 

consider a recommendation regarding a 

pilot project aimed at identifying 

methods and strategies to improve 

federal/state collaboration on consumer 

complaint processing. A 2nd 

mstockstill on DSKH9S0YB1PROD with NOTICES